The Next Chapter in Obesity Therapeutics: Vial's INHBE siRNA Draws KOL Praise as a Next-Generation Obesity Therapy

Barchart · 23h ago

EXECUTIVE SUMMARY

SAN FRANCISCO, Dec. 16, 2025 /PRNewswire/ -- Vial, a clinical-stage biotech company, today announced growing enthusiasm among metabolic disease KOLs for Vial's INHBE siRNA, a first-in-class, liver-targeted (GalNAc-conjugated) siRNA therapy that silences INHBE and its gene product, Activin E. With mounting evidence linking this pathway to energy expenditure and fat metabolism, Vial's INHBE is emerging as a promising new approach and new siRNA therapeutic to drive quality fat loss and improved body composition, potentially complementing or exceeding the effects of GLP-1-based therapies.

Read more at prnewswire.com

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.